Modern vaccine, antibodies induced by the company’s anti-Covid product mRna-1273 are present 6 months after the second dose. This was announced by the American company, based on a study that analyzed 33 healthy adults involved in the phase 1 trial conducted on the shield product, led by the US National Institutes of Health (Nih). The data are published in the Letter to Editor of the ‘New England Journal of Medicine’. “Studies are underway that monitor immune responses beyond 6 months,” adds the pharmaceutical company.
“We are pleased that these new data show the persistence of antibodies for 6 months after the second dose of our Covid-19 vaccine – said Stéphane Bancel, CEO of Moderna – This gives us further confidence in the protection offered by our vaccine. We remain committed to continue to tackle the Covid-19 pandemic “.
The company recalls that it is also pursuing a clinical development strategy against emerging variants of the Sars-CoV-2 coronavirus. In addition, Niaid (National Institute of Allergy and Infectious Diseases), directed by Anthony Fauci, will conduct a phase 1 clinical trial to evaluate modified monovalent and multivalent mRna-1273 vaccines in naïve individuals (not yet vaccinated), both as a booster in people previously vaccinated with mRna-1273.